eyeforpharma The Marketing Disruption Summit

eyeforpharma2 - 3 October 2019, Philadelphia, USA.
It's 2019 and Marketing is changing. Your customers' expectations have shifted to ‘one-click’. They expect more, they’re used to intuitive consumer interactions, and now they're looking at pharma.

Providing the seamless, personalized experience you've been dreaming about has never seemed closer. But marketers can't do it alone.

The Marketing Disruption Summit attendance is already ahead of expectations, with groups of industry leaders from across Marketing, Strategy, Data and IT already booked to delve deep into specifics with talks, workshops and case studies from top pharma, and equip themselves to be the key changemakers at home.

On current predictions, tickets will sell out this year. Ensure you have a place reserved at the only event where pharma marketing, data & IT change makers redefine customer interaction.

Reach out like never before

With Industry Leading Speakers carefully selected to cover every aspect of the back and front-end customer cycle, and an agenda designed to provide solutions to all the collaborative problems holding back your customer engagement:

Including:

  • Martina Flammer SVP customer value, Boehringer Ingelheim
  • Krishna Cheriath Chief Data Officer BMS
  • Alessandra Almeida Snr Director, Global Head of Master Data Management, Sanofi
  • Ignacio Quiles lara exec director global marketing and commercial ops, Abbvie
  • Ramon Vega head of global pharma marketing IT, Merck
  • Renaud Sermondade Head of insights and analytics, Sanofi

Unite to exceed changing customer demands

Marketers: Understand the technical capabilities within your business, build results-based strategies, and unite teams behind your vision.

Data: Communicate your capabilities and gain vital authority in strategic conversations.

Technology: Show stakeholders what your internal teams can do and inspire new strategies with innovation.

Together: Build cross functional strategies to revolutionize, personalize and redefine customer interaction.

World Pharma News readers can benefit from an exclusive discount, just use the code WPN300 to save $300 when you register here

For further information, please visit:
https://www.eyeforpharma.com/marketingusa/

About eyeforpharma

Our mission is to make pharma more open and valued. The ultimate driver for the pharmaceutical industry's health is meeting the needs of patients, otherwise it will cease to matter. For healthcare to be as good as it could be, the strength, skills and resources of our industry need to be fully integrated into health outcomes and we need pharma experience at the decision-making table. We believe the industry must focus on a business model combining service with product, with patients at the centre.

Most Popular Now

Johnson & Johnson announces European Commissio…

Johnson & Johnson (NYSE: JNJ) (the Company) announced the European Commission (EC), acting on behalf of the European Union (EU) Member States, has approved an Advance Pur...

BioNTech and Pfizer initiate rolling submission to…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced the initiation of a rolling submission to the European Medicines Agency (EMA) for BNT162b2, the lea...

Vir Biotechnology and GSK announce global expansio…

Vir Biotechnology, Inc. (Nasdaq: VIR) and GlaxoSmithKline plc (LSE/NYSE: GSK) announced the global expansion to Phase 3 of the COMET-ICE (COVID-19 Monoclonal antibody Eff...

Johnson & Johnson initiates pivotal global Pha…

Johnson & Johnson (NYSE: JNJ) (the Company) announced the launch of its large-scale, pivotal, multi-country Phase 3 trial (ENSEMBLE) for its COVID-19 vaccine candidate, J...

COVID-19 Long-Acting AntiBody (LAAB) combination A…

AstraZeneca's long-acting antibody (LAAB) combination, AZD7442, will advance into two Phase III clinical trials in more than 6,000 participants at sites in and outside th...

COVID-19 vaccine AZD1222 clinical trial resumed in…

The Phase I/II clinical trial for the COVID-19 vaccine AZD1222 has resumed in Japan after discussion with the Japanese Pharmaceuticals and Medical Devices Agency (PMDA). ...

Adequate levels of vitamin D reduces complications…

Hospitalized COVID-19 patients who were vitamin D sufficient, with a blood level of 25-hydroxyvitamin D of at least 30 ng/mL (a measure of vitamin D status), had a signif...

Gilead Sciences signs joint procurement agreement …

Gilead Sciences (Nasdaq: GILD) and the European Commission signed a joint procurement agreement (JPA) that will enable rapid and equitable access to Veklury® (remdesivir)...

Protective antibodies persist for months in surviv…

People who survive serious COVID-19 infections have long-lasting immune responses against the virus, according to a new study led by researchers at Massachusetts General ...

Potential COVID-19 vaccines not affected by domina…

Vaccines currently being developed for COVID-19 should not be affected by recent mutations in the virus, according to a new study involving a University of York virologis...

Regeneron's REGN-COV2 antibody cocktail reduced vi…

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced the first data from a descriptive analysis of a seamless Phase 1/2/3 trial of its investigational antibody cockta...

Popular COVID-19 conspiracies linked to vaccine 'h…

A new study of beliefs and attitudes toward COVID-19 in five different countries - UK, US, Ireland, Mexico and Spain - has identified how much traction some prominent con...